Companies Stand By MS Drug After Illnesses

Monday, August 4, 2008 - 08:56 in Health & Medicine

Biogen Idec Inc. and Elan Corporation defended Tysabri on Friday, saying the treatment is still worth the risk to patients.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net